Report of the 4th meeting on the "Evaluation of pandemic influenza prototype vaccines in clinical trials". World Health Organization, Geneva, Switzerland, 14-15 February 2008

Vaccine

Volumn 26, Issue 39, 2008, Pages 4975-4977

  Girard, Marc ^a   Palkonyay, Laszlo ^b   Kieny, Marie Paule ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AF 03; AS 03; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; AVIAN INFLUENZA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H5N2; PANDEMIC; PRIORITY JOURNAL; STANDARDIZATION; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS NEUTRALIZATION;

CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEROLOGIC TESTS; SWITZERLAND; VACCINES, ATTENUATED; VACCINES, SUBUNIT; WORLD HEALTH ORGANIZATION;

EID: 50549099077     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.04.050     Document Type: Conference Paper

References (13)

1. http://www.who.int/vaccine_reseach/diseases/influenza/meeting_120707/en/index.html
2. http://www.who.int/vaccine_research/diseases/ari/final_report_stockpile_meeting.pdf
3. http://www.who.int/vaccine_research/diseases/influenza/meeting_071203/en/index.html
4. Writing Committee of second World Health Organization consultation on clinical aspects of human infection with avian influenza A (H5N1) virus. New Engl J Med 358 (2008) 261-273
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
6. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
7. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
8. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
9. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
10. Normile D. Flu virus research yields results but no magic bullet for pandemic. Science 319 (2008) 1178-1179
11. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole- virion influenza A (H5N1) vaccine: a phase I randomized controlled trial. Lancet 368 (2006) 991-997
12. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 7 (2007) 685-696
13. Tam J.S., Capeding M.R., Lum L.C., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26 7 (2007) 619-628